A nickel-catalyzed
method for the site-selective hydrogen isotope
exchange (HIE) of C(sp2)–H bonds in nitrogen heteroarenes
is described and applied to the tritiation of pharmaceuticals. The
α-diimine nickel hydride complex [(iPrDI)Ni(μ2–H)]2 (iPrDI = N,N′-bis(2,6-diisopropylphenyl)-2,3-butanediimine)
mediates efficient HIE when employed as a single component precatalyst
or generated in situ from readily available and air-stable metal and
ligand precursors (iPrDI, [(NEt3)Ni(OPiv)2]2 (Piv = pivaloyl) and (EtO)3SiH).
The nickel catalyst offers distinct advantages over existing methods,
including: (i) high HIE activity at low D2 or T2 pressure; (ii) tolerance of functional groups, including aryl chlorides,
alcohols, secondary amides, and sulfones; (iii) activity with nitrogen-rich
molecules such as the chemotherapeutic imatinib; and (iv) the ability
to promote HIE in sterically hindered positions generally inaccessible
with other transition metal catalysts. Representative active pharmaceutical
ingredients were tritiated with specific activities in excess of the
thresholds required for drug absorption, distribution, metabolism,
and excretion studies (1 Ci/mmol) and for protein receptor–ligand
binding assays (15 Ci/mmol). The activity and selectivity of the nickel-catalyzed
method are demonstrated by comparison with the current state-of-the-art
single-site (iridium and iron) and heterogeneous (Raney nickel and
rhodium black) catalysts. A pathway involving C(sp2)–H
activation by a α-diimine nickel hydride monomer is consistent
with the experimentally measured relative rate constants for HIE with
electronically disparate pyridines, the pressure-dependence of activity,
positional selectivity preferences, and kinetic isotope effects.